Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 28 August 2018
Vedrop is indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis, from birth (full term newborns) up to 18 years of age.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Discover an overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The aim of this study is to evaluate bone microarchitecture of paediatric CF patients matched to sex-age-pubertal status-healthy volonteers. In...
Added 6 years ago
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation
To evaluate the safety of long-term ivacaftor treatment in subjects with cystic fibrosis (CF)
Added 7 years ago
A Phase 3, 2 Part, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX 770 in Subjects Aged 6 to 11 Years with Cystic Fibrosis and the G551D Mutation
Part A: To evaluate the pharmacokinetics of a single dose of orally administered VX 770 treatment in subjects 6 to...
Added 10 years ago
The aim of this study is then to determine the tolerance and acceptability of an oral solution of glibenclamide (Glinbentek) developed and dedicated to pediatric patients with neonatal diabetes secondary to mutation in potassium channels.
Added 4 months ago
The purpose of this study is to investigate long term response of sulfonylurea and glucose control in children with diabetes due to mutations in KCNJ11 that have been switched from insulin injections to sulfonylurea tablets.
Added 4 months ago
Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide.
Irritable bowel syndrome (IBS) is a complex functional gastrointestinal disorder that is exceedingly common in clinical practice. IBS with predominant constipation (IBS-C) is a subtype of IBS that accounts for more than a third of the IBS diagnosed.
Added 5 months ago
Eluxadoline (Truberzi) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist.
Added 1 year ago
Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease.
Introduction: Iron deficiency anemia affects up to three quarters of patients with inflammatory bowel disease (IBD). It can significantly impact...
Added 2 years ago
Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide.
Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents...
Added 4 years ago
Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer
The number of patients with chronic gastrointestinal (GI) symptoms after cancer therapies which have a moderate or severe impact on quality of life is similar to the number diagnosed with inflammatory bowel disease annually.
Added 6 years ago
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Added 3 years ago
This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder.
Added 8 years ago
This guideline applies to children younger than 5 years who present to a healthcare professional for advice in any setting.
Added 9 years ago
|Agency product number||EMEA/H/C/000920|
|Date First Approved||24-07-2009|
|Type||Medicinal product subject to restricted medical prescription|
|Marketing authorisation holder||Orphan Europe S.A.R.L.|
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti